Incretin Co-Agonists Revolutionize Treatment for Heart and Metabolic Diseases
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.
Background
Type 2 Diabetes Mellitus (T2DM) and obesity are major global health challenges, often leading to severe cardiovascular complications and significantly impacting quality of life. Traditional therapeutic approaches frequently fall short in achieving comprehensive glycemic control and substantial, sustained weight loss. This review synthesizes the current understanding of incretin co-agonists, highlighting their potential to transform cardiometabolic healthcare by addressing these multifaceted and interconnected health issues more effectively.